RT Journal Article
SR Electronic
T1 Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.03.21266419
DO 10.1101/2021.12.03.21266419
A1 Hanson, Kayla E.
A1 Goddard, Kristin
A1 Lewis, Ned
A1 Fireman, Bruce
A1 Myers, Tanya R.
A1 Bakshi, Nandini
A1 Weintraub, Eric
A1 Donahue, James G.
A1 Nelson, Jennifer C.
A1 Xu, Stan
A1 Glanz, Jason M.
A1 Williams, Joshua T.B.
A1 Alpern, Jonathan D.
A1 Klein, Nicola P.
YR 2021
UL http://medrxiv.org/content/early/2021/12/05/2021.12.03.21266419.abstract
AB Importance Post-authorization monitoring of vaccines in a large population can detect rare adverse events not identified in clinical trials including Guillain-Barré syndrome (GBS). GBS has a background rate of 1-2 per 100,000 person-years.Objective To 1) describe cases and incidence of GBS following COVID-19 vaccination, and 2) assess the risk of GBS after vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines.Design Interim analysis of surveillance data from the Vaccine Safety Datalink.Setting Eight participating integrated healthcare systems in the United States.Participants 10,158,003 individuals aged ≥12 years.Exposures Receipt of Ad.26.COV2.S, BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) COVID-19 vaccine.Main Outcomes and Measures GBS with symptom onset in the 1-84 days after vaccination as confirmed by medical record review and adjudication. Descriptive characteristics of confirmed cases, GBS incidence rates during postvaccination risk intervals after each type of vaccine compared to the background rate, rate ratios (RRs) comparing GBS incidence in the 1-21 vs. 22-42 days postvaccination, and RRs directly comparing risk of GBS after Ad.26.COV2.S vs. mRNA vaccination, using Poisson regression adjusted for age, sex, race/ethnicity, site, and calendar day.Results From December 13, 2020 through November 13, 2021, 14,723,318 doses of COVID-19 vaccines were administered, including 467,126 Ad.26.COV2.S, 8,573,823 BNT162b2, and 5,682,369 mRNA-1273 doses. Eleven cases of GBS after Ad.26.COV2.S were confirmed. The unadjusted incidence rate of confirmed cases of GBS per 100,000 person-years in the 1-21 days after Ad.26.COV2.S was 34.6 (95% confidence interval [CI]: 15.8-65.7), significantly higher than the background rate, and the adjusted RR in the 1-21 vs. 22-42 days following Ad.26.COV2.S was 6.03 (95% CI: 0.79-147.79). Thirty-four cases of GBS after mRNA vaccines were confirmed. The unadjusted incidence rate of confirmed cases per 100,000 person-years in the 1-21 days after mRNA vaccines was 1.4 (95% CI: 0.7-2.5) and the adjusted RR in the 1-21 vs. 22-42 days following mRNA vaccines was 0.56 (95% CI: 0.21-1.48). In a head-to-head comparison of Ad.26.COV2.S vs. mRNA vaccines, the adjusted RR was 20.56 (95% CI: 6.94-64.66).Conclusions and Relevance In this interim analysis of surveillance data of COVID-19 vaccines, the incidence of GBS was elevated after Ad.26.COV2.S. Surveillance is ongoing.Competing Interest StatementDr. Klein reports research support from Pfizer for COVID-19 vaccine clinical trials and Pfizer, Merck & Co., GlaxoSmithKline, Sanofi Pasteur, and Protein Science (now Sanofi Pasteur) for unrelated studies. Dr. Donahue reports research support from Janssen for an unrelated study. Dr. Nelson reports research support from Moderna for service on a COVID-19 vaccine data safety monitoring board. Dr. Alpern reports funding from Arnold Ventures for unrelated work. None of the other co-authors have disclosures to report.Clinical Protocols https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/emergencypreparedness/index.html Funding StatementThis study was supported by the Centers for Disease Control and Prevention (CDC), contract number 200-2012-53587-0014.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was approved by the Institutional Review Boards with a waiver of informed consent at Kaiser Permanente: Colorado, Northern California, Northwest, Southern California, and Washington; Marshfield Clinic; HealthPartners; and Denver Health. The Centers for Disease Control and Prevention (CDC) determined that this activity was public health surveillance (45 C.F.R. part 46.102(l)(2)) and thus did not require IRB review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesVSD data are not publicly available but access may be granted through collaboration with VSD sites or the VSD data sharing program. Please visit https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/accessing-data.html for more information.